image
Healthcare - Biotechnology - NASDAQ - IE
$ 12.54
-5.93 %
$ 5.18 B
Market Cap
-2.85
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one AMRN stock under the worst case scenario is HIDDEN Compared to the current market price of 12.5 USD, Amarin Corporation plc is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one AMRN stock under the base case scenario is HIDDEN Compared to the current market price of 12.5 USD, Amarin Corporation plc is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one AMRN stock under the best case scenario is HIDDEN Compared to the current market price of 12.5 USD, Amarin Corporation plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AMRN

image
$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
229 M REVENUE
-25.51%
-91.8 M OPERATING INCOME
-35.82%
-82.2 M NET INCOME
-39.03%
-31 M OPERATING CASH FLOW
-450.87%
-46 M INVESTING CASH FLOW
-80.14%
-1.44 M FINANCING CASH FLOW
-627.39%
42 M REVENUE
-32.56%
-16.8 M OPERATING INCOME
68.10%
-15.7 M NET INCOME
67.41%
-12.5 M OPERATING CASH FLOW
6.39%
12.1 M INVESTING CASH FLOW
153.02%
-1.12 M FINANCING CASH FLOW
-6582.35%
Balance Sheet Amarin Corporation plc
image
Current Assets 595 M
Cash & Short-Term Investments 294 M
Receivables 122 M
Other Current Assets 179 M
Non-Current Assets 90 M
Long-Term Investments 0
PP&E 7.61 M
Other Non-Current Assets 82.3 M
42.93 %17.84 %26.10 %12.01 %Total Assets$685.3m
Current Liabilities 180 M
Accounts Payable 40.4 M
Short-Term Debt 0
Other Current Liabilities 140 M
Non-Current Liabilities 19.2 M
Long-Term Debt 7.72 M
Other Non-Current Liabilities 11.5 M
20.27 %70.08 %3.88 %5.77 %Total Liabilities$199.2m
EFFICIENCY
Earnings Waterfall Amarin Corporation plc
image
Revenue 229 M
Cost Of Revenue 150 M
Gross Profit 81.4 M
Operating Expenses 173 M
Operating Income -91.8 M
Other Expenses -9.61 M
Net Income -82.2 M
250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)229m(150m)81m(173m)(92m)10m(82m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
35.60% GROSS MARGIN
35.60%
-40.15% OPERATING MARGIN
-40.15%
-35.95% NET MARGIN
-35.95%
-16.90% ROE
-16.90%
-11.99% ROA
-11.99%
-19.34% ROIC
-19.34%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Amarin Corporation plc
image
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)(200m)(200m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -82.2 M
Depreciation & Amortization 3.01 M
Capital Expenditures 0
Stock-Based Compensation 17.7 M
Change in Working Capital 36.2 M
Others -9.23 M
Free Cash Flow -31 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Amarin Corporation plc
image
Wall Street analysts predict an average 1-year price target for AMRN of $2.17 , with forecasts ranging from a low of $1.5 to a high of $3 .
AMRN Lowest Price Target Wall Street Target
1.5 USD -88.04%
AMRN Average Price Target Wall Street Target
2.17 USD -82.72%
AMRN Highest Price Target Wall Street Target
3 USD -76.08%
Price
Max Price Target
Min Price Target
Average Price Target
16161414121210108866442200Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Amarin Corporation plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
102 K USD 1
9-12 MONTHS
7. News
Amarin (AMRN) Now Trades Above Golden Cross: Time to Buy? From a technical perspective, Amarin Corporation PLC (AMRN) is looking like an interesting pick, as it just reached a key level of support. AMRN's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world. zacks.com - 2 weeks ago
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? Here is how Amarin (AMRN) and GSK (GSK) have performed compared to their sector so far this year. zacks.com - 2 weeks ago
Amarin (AMRN) Upgraded to Strong Buy: What Does It Mean for the Stock? Amarin (AMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 3 weeks ago
Best Momentum Stocks to Buy for June 10th AMRN, FIX and PATH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 10, 2025. zacks.com - 3 weeks ago
New Strong Buy Stocks for June 10th FIX, GHLD, AMRN, VCISY and NWFL have been added to the Zacks Rank #1 (Strong Buy) List on June 10, 2025. zacks.com - 3 weeks ago
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis. zacks.com - 1 month ago
Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript Amarin Corporation plc (NASDAQ:AMRN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Mark Marmur - Vice President of Corporate Communications and Investor Relations Aaron Berg - President and Chief Executive Officer Peter Fishman - Vice President and Global Controller Steven Ketchum - Executive Vice President, President of R&D and Chief Scientific Officer Conference Call Participants Operator Welcome to Amarin Corporation's Conference Call to discuss its First Quarter 2025 Business Update and Financial Results. I would like to turn the conference call over to Mark Marmur, Vice President, Corporate Communications and Investor Relations at Amarin. seekingalpha.com - 1 month ago
Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement -- Nasdaq Compliance Follows ADS Ratio Change to Secure Company's Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA – globenewswire.com - 2 months ago
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 DUBLIN and BRIDGEWATER, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin's senior management team to discuss its first quarter 2025 results followed by Q&A on Wednesday, May 7th, 2025, at 8:00 a.m. ET. globenewswire.com - 2 months ago
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change DUBLIN and BRIDGEWATER, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today confirmed that April 11, 2025 will be the effective date for the Company's previously announced Ratio Change on its American Depositary Shares (“ADS”) -- an action in which the Company will effect a ratio change from one (1) ADS representing one (1) ordinary share to a new ratio of one (1) ADS representing twenty (20) ordinary shares (the "Ratio Change"). globenewswire.com - 2 months ago
Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately. globenewswire.com - 2 months ago
Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, the Managing Director of JEC Capital Partners (together with certain of their affiliates, the “Concerned Shareholder Group” or “we”), who collectively own approximately 15 million shares of Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”), today issued the following open letter to the Company's Board of Directors. *** Amarin Corporation plc ATTN: Board of Directors (the “Board”) 88 Harcourt Street Dublin 2, Ireland. businesswire.com - 3 months ago
8. Profile Summary

Amarin Corporation plc AMRN

image
COUNTRY IE
INDUSTRY Biotechnology
MARKET CAP $ 5.18 B
Dividend Yield 0.00%
Description Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Contact Grand Canal Docklands, Dublin, 2 https://www.amarincorp.com
IPO Date April 1, 1993
Employees 275
Officers Dr. Nabil Abadir Chief Medical Officer of Global Medical Affairs Dr. Steven B. Ketchum Ph.D. Executive Vice President, President of Research & Development and Chief Scientific Officer Mr. Jonathan N. Provoost Executive Vice President, Chief Legal & Compliance Officer and Secretary Mr. Laurent Abuaf President of Europe & Senior Vice President Mr. Jordan Zwick Senior Vice President of Corporate Business Development & Investor Relations Mr. Aaron D. Berg Chief Executive Officer, President & Director Mr. Peter L. Fishman Chief Financial Officer Dr. David Keenan Ph.D. Executive Vice President of Technical Operations & President of Europe